Thyroid Gland Anaplastic Carcinoma

This case presents as a pitfall due to squamous differentiation in anaplastic thyroid carcinoma, which was initially misinterpreted as metastatic squamous cell carcinoma on fine needle aspiration (FNA) of the lymph node in the neck. Subsequent surgical resection reveals a unique rare occurrence of isolated anaplastic transformation of tall cell PTC in the metastatic lymph nodes, associated with the extremely rare co-occurrence of BRAF p.V600E and KRAS p.G12R mutations.

P1, N=72, Not yet recruiting, Sun Pharmaceutical Industries Limited

Collectively, our findings highlight the therapeutic potential of KU-57788 in ATC while revealing an intrinsic resistance mechanism mediated by DRP1 activation and the potential involvement of the NRF2/SLC7A11/GSH axis. More importantly, we provide strong evidence that combining KU-57788 with ferroptosis inducers significantly enhances its anticancer efficacy, offering a promising therapeutic strategy for ATC.

Mechanistically, ICCR strengthened tumor cell engagement, promoted selection and expansion of tumor-specific TCR clonotypes, and amplified downstream signaling pathways. These findings identify ICCR as a strategy that leverages an immune synapse-mimetic mechanism to enhance the function of low-activity tumor-specific TCRs and improve T cell responses in solid tumor microenvironments.

TAZ loss represses the UPR, reverses the inhibition of protein synthesis, and triggers increased cell death by ferroptosis in dabrafenib-treated ATC. Collectively, our findings unveil TAZ as a new target to overcome resistance to BRAF inhibitors in undifferentiated thyroid cancer.

In each molecular category, secondary alterations can occur; most notably TERT promoter and TP53 mutations occur with increasing frequency in high-grade differentiated, poorly differentiated, and anaplastic thyroid carcinomas. This article will review the diagnostic, prognostic, and therapeutic significance of molecular alterations across the spectrum of follicular cell derived thyroid tumors and discuss strategies for investigating unusual molecular alterations encountered in clinical practice.

These findings highlight ATP1B3, TFF3, LGALS1, ADAM12, and COL1A2 as potential disulfidptosis-related biomarkers in ATC. This study provides a theoretical foundation for understanding the role of disulfidptosis in ATC pathogenesis and suggests that ATP1B3 may serve as a promising therapeutic target.

The Idylla BRAF assay delivers ultrarapid results that are both reliable and accurate with high success rates, particularly on ScfDNA samples. ScfDNA samples also have the fastest TAT because no histologic processing or pre-extraction are required for testing.

IBC induces apoptosis and pyroptosis, with caspase-dependent Poly ADP-ribose Polymerase (PARP) and Gasdermin E (GSDME) cleavage simultaneously. This study reveals a novel function of IBC in inducing pyroptosis in tumor cells, expands its known pharmacological spectrum and highlights its value as a therapeutic agent for ATC.

Combining ICIs with targeted therapies or adoptive cell therapies is being explored to overcome resistance and improve efficacy. However, challenges such as tumor heterogeneity and immune evasion mechanisms persist.

The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

The study demonstrated that ketone body metabolite AcAc inhibits the proliferation, migration, and invasion of ATC cells and induces cell cycle arrest by inducing autophagy. Ketogenic diet provides a new strategy for the treatment of ATC.